Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which drug is best for pulmonary hypertensive crisis? new trial aims to find out

NCT ID NCT07667829

Disease control Sponsor: China National Center for Cardiovascular Diseases Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This trial will compare three drugs—dopamine, norepinephrine, and epinephrine—to see which works best for people experiencing a pulmonary hypertensive crisis, a life-threatening spike in blood pressure in the lungs. The study will enroll 75 adults with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension who are hospitalized. The main goal is to see which drug reduces the risk of death within 28 days, while also monitoring side effects like irregular heartbeats.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
dopamine, norepinephrine, and epinephrine
What this could lead to
If this trial succeeds, it could identify the safest and most effective vasopressor for managing pulmonary hypertensive crisis, potentially improving survival and reducing complications.
What could go wrong
This is a small, early-stage trial (75 participants) comparing existing drugs, so results may not be definitive. The study is not yet recruiting, and outcomes may not apply to all patients with pulmonary hypertension.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 75 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Jan 2029

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age \> 18 years old; 2. Signed informed consent form; 3. Confirmed diagnosis of arterial pulmonary hypertension (PAH) and/or chronic thromboembolic pulmonary hypertension (CTEPH); 4. Presenting with manifestations of pulmonary hypertensive crisis; 5. Receiving both diagnosis and treatment in-hospital; 6. No intravenous administration of the vasopressor drugs (including dopamine, norepinephrine, and epinephrine) under study at enrollment. Exclusion Criteria: 1. At SCAI stage D or stage E ; 2. Patients who only receive a diagnosis but no treatment in the hospital; 3. Uncontrolled hyperthyroidism; 4. Complicated with angle-closure glaucoma; 5. Hypersensitivity to the study drug; 6. Ongoing use of halogenated hydrocarbon general anesthetics such as cyclopropane and halothane; 7. Ongoing use of monoamine oxidase inhibitor (MAOI) antidepressants or anti-Parkinson drugs (phenelzine, tranylcypromine, isocarboxazid, moclobemide); 8. Pregnancy; 9. Already receiving the vasopressor drugs (dopamine, norepinephrine, epinephrine) under study at enrollment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic thromboembolic pulmonary hypertension (cteph) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cardiovascular disorder chronic thromboembolic pulmonary hypertension heart failure pulmonary arterial hypertension pulmonary hypertension vascular disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic thromboembolic pulmonary hypertension (cteph) Hypertension, pulmonary Pulmonary arterial hypertension (PAH)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Chinese Academy of Medical Sciences, Fuwai Hospital

    Beijing, Beijing Municipality, 10037, China

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, 510180, China

  • Zhongnan Hospital of Wuhan University

    Wuhan, Wuhan, 430072, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.